

DAFTAR PUSTAKA

1. Situasi Kesehatan Gigi dan Mulut 2019. <https://www.kemkes.go.id/article/view/20030900005/situasikesehatan-gigi-dan-mulut>
2. Al-Hamed, F S., Mohammed, M., Haider, A., Jesus, T., Zahi, B., and Faleh, T. 2019. Regenerative Effect of Platelet Concentrate in Oral Craniofacial Regeneration *Frontiers in Cardiovascular Medicine*. 3(1): 216–224.
3. Diah, Widodorini T, Nugraheni NE. Perbedaan angka kejadian gingivitis antara usia pra-pubertas dan pubertas di Kota Malang. 2018. *E-Pro dental J Dent*;2(1):109
4. Tyas WE, Susanto HE, Adi MS, Udiyono A. Gambaran kejadian penyakit periodontal pada usia dewasa muda (15-30 tahun) di Puskesmas Srandol Kota Semarang. 2016. *JKM*;4(4):510
5. Samaranayake LP, Jones BM, Scully C. *Microbiology of Periodontal Disease* in: Samaranayake LP, Jones BM, Scully C, eds. *Essential Microbiology for Dentistry*. Second edition ed. Toronto: Churchill Livingstone, 2002;224-232.
6. Handini AF, Pratiwi, Sunnah TD. Regenerasi sel ligamen periodontal dengan kolagen sisik ikan nila (*Oreochromis niloticus*). *Media Dental Intelektual Journal* 2021; 3(1):44.
7. Ramadhani ZF, Putri DKT, Cholil. Prevalensi Penyakit Periodontal Pada Perokok Di Lingkungan Batalyon Infanteri 621/Manuntung Barabai Hulu Sungai Tengah. *Dentino J Kedokt gigi*. 2014;II(2):116.

8. Windisch P, Szendrői-Kiss D, Horváth A, Suba Z, Gera I, Sculean A. Reconstructive periodontal therapy with simultaneous ridge augmentation. A clinical and histological case series report. *Clin Oral Investig*. 2008;12(3):257–64.
9. Wijayanto HD, Murdiastuti K. Perawatan Bonegraft dengan Penambahan Platelet-Rich Plasma dan Kolagen pada Kerusakan Infraboni. *Maj Kedokt Gigi Klin*. 2016;1(1):9
10. Chang Y, Cho B, Kim S, Kim J. Direct conversion of fibroblasts to osteoblasts as a novel strategy for bone regeneration in elderly individuals. *Exp Mol Med* [Internet]. 2019;51(5):1–8.
11. Schemitsch. E. H. Size Matters: defining critical in bone defect size! *Journal of orthopaedic trauma*. 2017;31(10), S20-S22
12. Khaerillah, M., & Almeshaly, H. Present strategies for critical bone defects regeneration. *Oral Health Case Reports*. 2016; 02(03). https://doi.org/10.1007/978-1-59745-347-9_34
13. Kripal, K., Sirajjudin, S., Reddy, S.S., Kumar P. Bone Engineering Using Human Demineralized Dentin Matrix (Autotooth Bone Graft) in the Treatment of Human Intra-bony Defects: A Case Report. *EC Dent Sci*. 2017;3:91–100
14. Oktawati S, Astuti LA. Perawatan bedah flap periodontal pada kasus periodontitis kronis: sebuah laporan kasus. 2014. *As-Syifaa*;6(1):98-106
15. Baldwin, P., Li, D.J., Auston, D.A., Mir, H.S., Yoon, R.S., & Koval, K.J. Autograft, Allograft and bone graft substitutes: clinical evidence and

- indications for use in the setting of orthopaedic trauma surgery. *Journal of Orthopaedic Trauma*. 2019; 33(4), 203-213.
<https://doi.org/10.1097/BOT.0000000000001420>
16. Ezoddini-Ardakani F, Navab Azam A, Yassaei S, Fatehi F, Rouhi G. Effects of chitosan on dental bone repair. *Health (Irvine Calif)*. 2011;03(04):200–5.
 17. Battafarano G, Rossi M, De Martino V, Marampon F, Borro L, Secinaro A, et al. Strategies for bone regeneration: From graft to tissue engineering. *Int J Mol Sci*. 2021;22(3):1–22.
 18. Sataloff RT, Johns MM, Kost KM. *Graf Tulang & Material Pengganti Tulang, Karakteristik dan Strategi Aplikasi Klinis*. pertama. Surabaya: Airlangga University press; 2018. 77 p.
 19. Zhao R, Yang R, Cooper PR, Khurshid Z, Shavandi A, Ratnayake J. Bone grafts and substitutes in dentistry: a review of concept trends and development. 2021;26(3007);1.
 20. Sari, R.P dkk. Pengembangan produk bone grafting dari cangkang kerang darah dan teripang emas (biota laut). Universitas Hang Tuah Surabaya 2016; simlitabmas.ristekdikti.go.id/kinerja/penelitianDitlitabmas.aspx
 21. Darwis D, Warastuti Y. Sintesis dan karakterisasi komposit hidroksiapatit (ha) sebagai graft tulang sintetik. *Jurnal Ilmiah Aplikasi Isotop dan Radiasi*. 2008; 4(2)
 22. Ferdiansyah et al. Regenerasi pada massive bone defect dengan bovine hydroxyapatite sebagai scaffold mesenchymal stem cell. <http://journal.unair.ac.id.2011>. Accessed 14 Mei 2015.

23. Wang W and Yeung KWK. Bone graft and biomaterial substitute for bone defect repair: A review. *Bioactive Materials*. 2017
24. Kapinas K and Delany AM. MicroRNA biogenesis and regulation of bone remodelling. *Arthritis Research & Therapy*. 2011; 13: 1-11.
25. Ardhiyanto, H.B. Peran hidroksiapatit sebagai bone graft dalam proses penyembuhan tulang. *Stomatognathic (J.K.G Unej)* Vol. 8 No. 2 2011: 118-21
26. Hardani PR, Lastianny SP, Herawati D. Pengaruh penambalan platelet-rich plasma pada cangkok tulang terhadap kadar osteocalcin cairan sulkus gingiva pada terapi poket infraboni. *Jurnal PDGI*. 2013; 62: 75-82.
27. Dincel YM. Bone graft types [internet]. Intech Open 2018 [cited 5 September 2021]. Available from: <https://cdn.intechopen.com/pdfs/62497.pdf>
28. Fesseha H, Fesseha Y. Bone grafting, its principle and application: a review. 2020. *Osteol Rheumatol Open J*.1(1):43
29. Hung NN. Basic knowledge of bone grafting [internet]. Researchgate.2016. [cited 5 September 2021]. Available from: <https://www.researchgate.net/publication/221929818>
30. Balaji VR, Manikandan D, Ramsundar A. Bone graft in Periodontics. *Matrix Sci Med*. 2020; 4:57
31. Listari KM, Ruhadi I, Ulfa N. Ekspresi RANKL pada defek tulang dengan pemberian *xenograft* dibandingkan dengan *xenograft* dan PRF. 2019. *E-Prodentia J Dent*;3(1):218.

32. Labres XR, Camps AR, Salas EJ, Albuquerque R, Ortega EV, Lopez-Lopez J. Graft materials in oral surgery: revision. 2014. *J Biomim Biomater Tissue Eng*;19(1):4
33. Titisinides S, Agrogiannis G, Karatzas T. Bone grafting materials in dentoalveolar reconstruction: a comprehensive review. 2019. *Jpn Dent Sci Rev*;55:30
34. Thahir H, setiawati D. Regenerative approach in the treatment of grade II furcation: a case report. *Journal of Dentomaxillofacial Science [Internet]*.2019; 4(1): 53-56.
35. Oktawati S, Mappangara S, Chandra H, et al. Effectiveness Nacre Pearl Shell (*Pinctada Maxima*) as Bone Graft for Periodontal Bone Remodeling. *Ann RSCB [Internet]*. 2021;25(3):8663–78.
36. Adam M, Thahir H, Supiaty, Achmad H, Putri SW, Azizah, dkk. The Potential of Golden Sea Cucumber (*Stichopus hermanii*) in the Regeneration of Periodontal Tissues: a Literature Review.2021;25(6). 4407-18.
37. Djais AI, Mappangara S, Gani A et al. The Effectiveness of Milkfish (*Chanos Chanos*) Scales Chitosan on Soft and Hard Tissue Regeneration In Tooth Extraction Socket: A Literature Review. *Annals of R.S.C.B. [Internet]*.2021; 25(3): 8729 – 8752.
38. Agustina N, Hasbullah ID, Panjaitan FUA. The effect of hydroxyapatite xenograft on haruan fish (*Channa striata*) bone on the number of osteoblast and osteoclast.2018. *Dentino Jur Ked Gi*;3(2):119-20

39. Wijayanto HD, Murdiastuti K. Perawatan *binegraft* dengan penambahan *platelet-rich fibrin plasma* dan kolagen pada kerusakan infraboni. 2015. MKGK;1(1):9
40. Mancini L, Fratini A, Marchetti E. Periodontal regeneration. 2021. MDPI;1:87
41. Prasetyo BC, Mustika I, Ismi N. Perawatan bedah periodontal regeneratif pada keterlibatan furkasi lesi endodontik-periodontik. 2021. Cakradonya Dent J;13(1):58
42. Cahaya C, Masulili SLC. Perkembangan terkini membran *guided tissue regeneration/guided bone regeneration* sebagai terapi regenerasi jaringan periodontal. 2015. Maj Ked Gi Ind;1(1):2-3
43. Hagi TT, Laugisch O, Ivanovic A, Sculean A, Mult HC. Regenerative periodontal therapy. 2014. Quintessence Int;45:185
44. Hassan, K.S., Marei, H.F., dan Alagl, A. S. Does grafting of third molar extraction sockets enhance periodontal measures in 30 to 35 year-old patients ?. J Oral Maxillofac Surg. 2012.:70:757-764
45. Hassan, K.S., Marei, H.F., dan Alagl, A. S. Does grafting of third molar extraction sockets enhance periodontal measures in 30 to 35 year-old patients? J Oral Maxillofac Surg. 2012.:70:757-764
46. Temmerman, A. et al. Bovine-derived xenograft in combination with autogenous bone chips versus xenograft alone for the augmentation of bony dehiscences around oral implants: A randomized, controlled, split-mouth clinical trial. Jurnal of Clinical Periodontology. 2019.; 00:1–10.

47. Jain, D et al. Clinical and radiologic evaluation of regenerative potential of nha paste and dbm in the treatment of periodontal intra-bony defects -a randomized control trial. *Journal of Clinical and Diagnostic Research*. 2016.; 10(9): ZC74-ZC79
48. Gorski, B., et al. Treatment of intrabony defects with modified perforated membranes in aggressive periodontitis: a 12-month randomized controlled trial. *Clinical Oral Investigations*. 2018; <https://doi.org/10.1007/s00784-018-2368-3>
49. Gamal, A. Y., Gaffar, K. A. dan Algezwy, O.A. Crevicular fluid growth factors release profile following the use of platelets rich fibrin (PRF) and plasma rich growth factors (PRGF) in treating periodontal intrabony defects (randomized clinical trial). *Journal of Periodontology*. 2016; .1902/jop.2016.150314
50. Aghazadeh, A. Perrson GR, dan Renvert S.A. A single-centre randomized controlled clinical trial on the adjunct treatment of intra-bony defects with autogenous bone or a xenograft: results after 12 months. *Jurnal of Clinical Periodontology*. 2012; 10.1111/j.1600-051X.2012.01880.x
51. Lekovic, V et al. Platelet-rich fibrin and bovine porous bone mineral vs. platelet-rich fibrin in the treatment of intrabony periodontal defects. *Journal Of Periodontal Research*. 2011; 10.1111/j.1600-0765.2011.01446.x
52. Cockerham, B. L. et al. Ridge augmentation comparing a cancellous block allograft to an osteoinductive demineralized bone matrix allograft: a

- randomized, controlled, blinded clinical trial. *The International Journal of Periodontics and Restorative Dentistry*/ 2020; 40(4)
53. Ramadhani, Z.F., Putri, D.K.T., dan Cholil. Prevalensi penyakit periodontal pada perokok di lingkungan batalyon infanteri 621/manuntung barabai hulu sungai tengah. *Dentino Jurnal Kesehatan Gigi*. 2014; 2 (2)
 54. Wijayanto, H. D. dan Murdiastuti. K. Perawatan bonegraft dengan penambahan platelet-rich plasma dan kolagen pada kerusakan infraboni. *MKGK*. 2015; 1(1): 9-13
 55. Prasetyo, B. C., Mustika, I. dan Ismi. N. Regenerative periodontal surgery therapy with furcation involvement endo-perio lesions. 2015; *Cakradonya Dent J*; 13(1): 56-62
 56. Handini, A.F, Pratiwi, R., dan Sunnah, T.D., Regenerasi sel ligamen periodontal dengan kolagen sisik ikan nila (*oreochromis niloticus*). *MEDALI Journal*. 2021; 3(1)
 57. Amid, R., et al. Structural and chemical features of xenograft bone substitutes: A systematic review of in vitro studies. 2020.
 58. Hardhani, P. R., Lastianny, S.P, dan Herawati, D., Pengaruh penambahan *platelet-rich plasma* pada cangkok tulang terhadap kadar *osteocalcin* cairan sulkus gingiva pada terapi poket infraboni. *Jurnal PDGI*. 2013; 62 (3). 75-82
 59. Polymeri, A. et al. Surgical treatment of peri-implantitis defects with two different xenograft granules: A randomized clinical pilot study. *Clin Oral Impl Res*. 2020; 00:1–14. Wiley online library

60. Elfana, A. et al. Alveolar ridge preservation using autogenous whole-tooth versus demineralized dentin grafts: A randomized controlled clinical trial. *Clin Oral Impl Res.* 2021; 32:539–548. [_wileyonlinelibrary.com/journal/clr](https://wileyonlinelibrary.com/journal/clr)
61. Drismayanti, I. dkk., The effect of bone graft and splitting osteotomy on development of the root of transplanted immature third molar. *Dentofasial.* 2010; 10 (8) 6-12
62. Hung, N.N., Basic knowledge of bone grafting. Military Academy of Medicine, 2016. <https://www.researchgate.net/publication/221929818>
63. Kurniawan, H. Efek pemberian kombinasi prf dengan xenograft dan alloplast terhadap jumlah osteoblast. Departemen Periodonsia, Fakultas Kedokteran Gigi Universitas Hang Tuah Surabaya. 2013.
64. Lee, J.S., Cha, J.K., and Kim, C.S. Alveolar ridge regeneration of damaged extraction sockets using deproteinized porcine versus bovine bone minerals: a randomized clinical trial. *Clin Implant Dent Relat Res.* 2018;1–9.
65. Cahaya, C., dan Masulili, S.L.C. Perkembangan terkini membran guided tissue regeneration/guided bone regeneration sebagai terapi regenerasi jaringan periodontal. *Maj Ked Gi Ind.* 2015; 1(1): 1 – 11
66. Wijayanto, H.D., dan Murdiastuti, K., Perawatan bonegraft dengan penambahan platelet-rich plasma dan kolagen pada kerusakan infraboni. *MKGK.* 2015; 1(1): 9-13

67. Listari, K. M., Ruhadi, I. dan Ulfa, N. Ekspresi rankl pada defek tulang dengan pemberian xenograft dibandingkan dengan xenograft dan PRF. *E-Prodentia Journal of Dentistry*. 2019; 3(1): 216-224. 10.21776/ub.eprodenta.2019.003.01.5
68. Renvert, S., Roos-Jansaker, AM, and Persson, GR. Surgical treatment of peri-implantitis lesions with or without the use of a bone substitute-a randomized clinical trial. *Journal of Clinical Periodontology*. 2018; 45(10), 1266–1274. <https://doi.org/10.1111/jcpe.12986>

**Lampiran 1a JBI Critical Appraisal Checklist untuk Studi Randomized
Controlled Trials**

JBI Critical Appraisal Checklist for Randomized Controlled Trials

Reviewer _____ Date _____
 Author Leukovic *et al.*, (2011) Year 2021 Record Number 1

	Yes	No	Unclear	NA
1. Was true randomization used for assignment of participants to treatment groups?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
2. Was allocation to treatment groups concealed?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
3. Were treatment groups similar at the baseline?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
4. Were participants blind to treatment assignment?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
5. Were those delivering treatment blind to treatment assignment?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6. Were outcomes assessors blind to treatment assignment?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
7. Were treatment groups treated identically other than the intervention of interest?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
8. Was follow up complete and if not, were differences between groups in terms of their follow up adequately described and analyzed?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
9. Were participants analyzed in the groups to which they were randomized?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
10. Were outcomes measured in the same way for treatment groups?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
11. Were outcomes measured in a reliable way?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
12. Was appropriate statistical analysis used?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
13. Was the trial design appropriate, and any deviations from the standard RCT design (individual randomization, parallel groups) accounted for in the conduct and analysis of the trial?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Overall appraisal: Include Exclude Seek further info

Comments (Including reason for exclusion)

Lampiran 1b *JBI Critical Appraisal Checklist* untuk *Studi Randomized Controlled Trials*

JBI Critical Appraisal Checklist for Randomized Controlled Trials

Reviewer _____ Date _____

Author Aghazaled et al (2012) Year 2021 Record Number 2

	Yes	No	Unclear	NA
1. Was true randomization used for assignment of participants to treatment groups?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
2. Was allocation to treatment groups concealed?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
3. Were treatment groups similar at the baseline?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
4. Were participants blind to treatment assignment?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
5. Were those delivering treatment blind to treatment assignment?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6. Were outcomes assessors blind to treatment assignment?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
7. Were treatment groups treated identically other than the intervention of interest?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
8. Was follow up complete and if not, were differences between groups in terms of their follow up adequately described and analyzed?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
9. Were participants analyzed in the groups to which they were randomized?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
10. Were outcomes measured in the same way for treatment groups?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
11. Were outcomes measured in a reliable way?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
12. Was appropriate statistical analysis used?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
13. Was the trial design appropriate, and any deviations from the standard RCT design (individual randomization, parallel groups) accounted for in the conduct and analysis of the trial?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Overall appraisal: Include Exclude Seek further info

Comments (Including reason for exclusion)

Lampiran 1c *JBI Critical Appraisal Checklist* untuk Studi *Randomized Control Trial*

JBI Critical Appraisal Checklist for Randomized Controlled Trials

Reviewer _____ Date _____
 Author Hassan et al, (2012) Year 2021 Record Number 3

	Yes	No	Unclear	NA
1. Was true randomization used for assignment of participants to treatment groups?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
2. Was allocation to treatment groups concealed?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
3. Were treatment groups similar at the baseline?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
4. Were participants blind to treatment assignment?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
5. Were those delivering treatment blind to treatment assignment?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6. Were outcomes assessors blind to treatment assignment?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
7. Were treatment groups treated identically other than the intervention of interest?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
8. Was follow up complete and if not, were differences between groups in terms of their follow up adequately described and analyzed?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
9. Were participants analyzed in the groups to which they were randomized?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
10. Were outcomes measured in the same way for treatment groups?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
11. Were outcomes measured in a reliable way?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
12. Was appropriate statistical analysis used?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
13. Was the trial design appropriate, and any deviations from the standard RCT design (individual randomization, parallel groups) accounted for in the conduct and analysis of the trial?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Overall appraisal: Include Exclude Seek further info

Comments (Including reason for exclusion)

**Lampiran 1d JBI Critical Appraisal Checklist untuk Studi Randomized
Controlled Trials**

JBI Critical Appraisal Checklist for Randomized Controlled Trials

Reviewer _____ Date _____

Author Gamal et al, (2016) Year 2021 Record Number 4

	Yes	No	Unclear	NA
1. Was true randomization used for assignment of participants to treatment groups?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
2. Was allocation to treatment groups concealed?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
3. Were treatment groups similar at the baseline?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
4. Were participants blind to treatment assignment?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
5. Were those delivering treatment blind to treatment assignment?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6. Were outcomes assessors blind to treatment assignment?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
7. Were treatment groups treated identically other than the intervention of interest?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
8. Was follow up complete and if not, were differences between groups in terms of their follow up adequately described and analyzed?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
9. Were participants analyzed in the groups to which they were randomized?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
10. Were outcomes measured in the same way for treatment groups?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
11. Were outcomes measured in a reliable way?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
12. Was appropriate statistical analysis used?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
13. Was the trial design appropriate, and any deviations from the standard RCT design (individual randomization, parallel groups) accounted for in the conduct and analysis of the trial?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Overall appraisal: Include Exclude Seek further info

Comments (Including reason for exclusion)

Lampiran 1e JBI Critical Appraisal Checklist untuk Studi Randomized Controlled Trials

JBI Critical Appraisal Checklist for Randomized Controlled Trials

Reviewer _____ Date _____

Author Jain et al (2016) Year 2021 Record Number 5

	Yes	No	Unclear	NA
1. Was true randomization used for assignment of participants to treatment groups?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
2. Was allocation to treatment groups concealed?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
3. Were treatment groups similar at the baseline?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
4. Were participants blind to treatment assignment?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
5. Were those delivering treatment blind to treatment assignment?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6. Were outcomes assessors blind to treatment assignment?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
7. Were treatment groups treated identically other than the intervention of interest?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
8. Was follow up complete and if not, were differences between groups in terms of their follow up adequately described and analyzed?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
9. Were participants analyzed in the groups to which they were randomized?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
10. Were outcomes measured in the same way for treatment groups?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
11. Were outcomes measured in a reliable way?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
12. Was appropriate statistical analysis used?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
13. Was the trial design appropriate, and any deviations from the standard RCT design (individual randomization, parallel groups) accounted for in the conduct and analysis of the trial?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Overall appraisal: Include Exclude Seek further info

Comments (Including reason for exclusion)

Lampiran 1f JBI Critical Appraisal Checklist untuk Studi Randomized Controlled Trials

JBI Critical Appraisal Checklist for Randomized Controlled Trials

Reviewer _____ Date _____
 Author Gorski et al, (2018) Year 2021 Record Number 6

	Yes	No	Unclear	NA
1. Was true randomization used for assignment of participants to treatment groups?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
2. Was allocation to treatment groups concealed?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
3. Were treatment groups similar at the baseline?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
4. Were participants blind to treatment assignment?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
5. Were those delivering treatment blind to treatment assignment?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6. Were outcomes assessors blind to treatment assignment?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
7. Were treatment groups treated identically other than the intervention of interest?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
8. Was follow up complete and if not, were differences between groups in terms of their follow up adequately described and analyzed?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
9. Were participants analyzed in the groups to which they were randomized?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
10. Were outcomes measured in the same way for treatment groups?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
11. Were outcomes measured in a reliable way?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
12. Was appropriate statistical analysis used?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
13. Was the trial design appropriate, and any deviations from the standard RCT design (individual randomization, parallel groups) accounted for in the conduct and analysis of the trial?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Overall appraisal: Include Exclude Seek further info

Comments (Including reason for exclusion)

**Lampiran 1g JBI Critical Appraisal Checklist untuk Studi Randomized
Controlled Trials**

JBI Critical Appraisal Checklist for Randomized Controlled Trials

Reviewer _____ Date _____

Author Temmerman et al (2019) Year 2021 Record Number 7

	Yes	No	Unclear	NA
1. Was true randomization used for assignment of participants to treatment groups?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
2. Was allocation to treatment groups concealed?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
3. Were treatment groups similar at the baseline?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
4. Were participants blind to treatment assignment?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
5. Were those delivering treatment blind to treatment assignment?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6. Were outcomes assessors blind to treatment assignment?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
7. Were treatment groups treated identically other than the intervention of interest?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
8. Was follow up complete and if not, were differences between groups in terms of their follow up adequately described and analyzed?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
9. Were participants analyzed in the groups to which they were randomized?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
10. Were outcomes measured in the same way for treatment groups?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
11. Were outcomes measured in a reliable way?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
12. Was appropriate statistical analysis used?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
13. Was the trial design appropriate, and any deviations from the standard RCT design (individual randomization, parallel groups) accounted for in the conduct and analysis of the trial?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Overall appraisal: Include Exclude Seek further info

Comments (Including reason for exclusion)

Lampiran 1h *JBI Critical Appraisal Checklist* untuk *Studi Randomized Controlled Trials*

JBI Critical Appraisal Checklist for Randomized Controlled Trials

Reviewer _____ Date _____

Author Cockerham et al (2020) Year 2021 Record Number 8

	Yes	No	Unclear	NA
1. Was true randomization used for assignment of participants to treatment groups?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
2. Was allocation to treatment groups concealed?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
3. Were treatment groups similar at the baseline?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
4. Were participants blind to treatment assignment?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
5. Were those delivering treatment blind to treatment assignment?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6. Were outcomes assessors blind to treatment assignment?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
7. Were treatment groups treated identically other than the intervention of interest?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
8. Was follow up complete and if not, were differences between groups in terms of their follow up adequately described and analyzed?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
9. Were participants analyzed in the groups to which they were randomized?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
10. Were outcomes measured in the same way for treatment groups?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
11. Were outcomes measured in a reliable way?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
12. Was appropriate statistical analysis used?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
13. Was the trial design appropriate, and any deviations from the standard RCT design (individual randomization, parallel groups) accounted for in the conduct and analysis of the trial?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Overall appraisal: Include Exclude Seek further info

Comments (Including reason for exclusion)

Lampiran 2 PRISMA (*Preferred Reporting Items for Systematic Reviews and Meta-Analyses*) Checklist

Section/Topic	Item No.	Checklist item
TITLE		
Title	1	Identify the report as a systematic review, meta-analysis, or both.
ABSTRACT		
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.
INTRODUCTION		
Rationale	3	Describe the rationale for the review in the context of what is already known.
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).
METHODS		
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.